TriSalus Thinks Its Drug/Device Strategy Can Optimize IO Regimens
Executive Summary
The firm licensed the TLR9 agonist SD-101 from Dynavax to test with its pressure-enabled drug delivery technology in liver and pancreatic settings where immuno-oncology has shown moderate efficacy or less.
You may also be interested in...
Deal Watch: AbbVie Exits Inherited CRISPR-Cas9 Team-Up With Editas
Editas regains rights to ocular programs first partnered with Allergan in 2017. Newly public F-star will focus on bispecific antibodies for cancer, TriSalus acquires oncology candidate from Dynavax.
The Other COVID-19 Vaccine Race: GSK Leads In Adjuvant Field, But Dynavax And Novavax Making Moves
The certainty that any COVID-19 vaccine will see demand outstrip supply could be an inflection point for the once-quiet field of novel vaccine adjuvant research, which promises to enhance immune response and lower the vaccine dose required.
Surefire Medical Inc.
Current embolic therapies for cancer have one major drawback. When they're introduced into a vessel through a catheter, reflux often occurs along the catheter, sending the medication backward into another vessel and into non-targeted tissue. The safety of these could greatly improve with Surefire Medical's new embolic therapy catheter. Surefire's initial therapeutic target is liver cancer.